Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma

Conditions

• Non-squamous, Non-Small Cell Lung Cancer

Interventions

• DRUG: afatinib

Sponsor

Boehringer Ingelheim